9M 2023 Financial Performance
9M 2023: APPENDIX
Other pharmaceuticals
Other pharmaceuticals revenue
(Quarterly DKKm)
2,000
1,500
Other pharmaceuticals revenue
(9M-DKKm)
5,400
4,500
3,600
-9%
reported
0%
reported
1,000
2,700
500
1,800
900
0
0
Q3.20
Q3.21
Q3.22
Q3.23
9M 2020
9M 2021
9M 2022
9M 2023
43
Total
Unless otherwise stated, growth rates are at CER. LoE: February 18, 2021. 1) Lundbeck has only promoted Northera, Onfi and Xenazine in the U.S.
Comments
•
Grew 3% (+0% reported) to DKK 2.6bn in 9M
2023
•
•
Down by 1% (-9% reported) to DKK 0.8bn in
Q3 2023
Around 15 mature products included
Biggest products are Azilect, Cipramil,
Cisordinol, Deanxit, Ebixa, Fluanxol, Northera,
Onfi, Selincro, Xenazine¹)
Ebixa impacted by VBP in China from Q4 2020
Onfi sales impacted by generic erosion from
October 2018
International Markets constitutes around 41%
of sales (9M 2023)View entire presentation